Open access
Open access
Powered by Google Translator Translator

Daily Archives: November 16, 2021

RCT: Intravenous immunoglobulins do not improve outcomes in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome.

16 Nov, 2021 | 08:48h | UTC

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

IDSA/ASM Consensus Review Document: Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping.

16 Nov, 2021 | 08:50h | UTC

Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: An IDSA/ASM Consensus Review Document – Clinical Infectious Diseases

News Release: New review article outlines potential of SARS-CoV-2 genetic sequencing in patient care – American Society for Microbiology

 

Review: Vaccine-induced immune thrombotic thrombocytopenia.

16 Nov, 2021 | 08:46h | UTC

Vaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology

Related:

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Commentary on Twitter

 

Covid: Austria introduces lockdown for unvaccinated.

16 Nov, 2021 | 08:43h | UTC

Covid: Austria introduces lockdown for unvaccinated – BBC

See also: Austria orders nationwide lockdown for the unvaccinated – Associated Press

 

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding.

16 Nov, 2021 | 08:42h | UTC

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding – The BMJ

 

Commentary on Twitter

 

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more.

16 Nov, 2021 | 08:41h | UTC

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used.

16 Nov, 2021 | 08:39h | UTC

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used – The Conversation

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

New WHO report maps barriers to insulin availability and suggests actions to promote universal access – “100 years after its discovery, insulin still out of reach for many living with diabetes”.

16 Nov, 2021 | 08:34h | UTC

News Release: New WHO report maps barriers to insulin availability and suggests actions to promote universal access – World Health Organization

Report: Keeping the 100-year-old promise: making insulin access universal – World Health Organization

Commentary: Half the People Living with Diabetes Can’t Afford Insulin, WHO Report Shows – Health Policy Watch

Related:

Editorial | Insulin for all: a hope yet to be realized.

One hundred years of insulin therapy.

The state of diabetes treatment coverage in 55 low-income and middle-income countries – fewer than one in ten people with diabetes in LMICs receive comprehensive care such as low-cost medicines to reduce blood sugar, blood pressure and cholesterol levels, in addition to counseling on diet, exercise and weight.

 

Commentary on Twitter (thread – click for more)

 

2021 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.

16 Nov, 2021 | 08:37h | UTC

2021 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Neonatal Life Support; Education, Implementation, and Teams; First Aid Task Forces; and the COVID-19 Working Group – Circulation (for an HTML version click here)

Top Things to Know: International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations (CoSTR) – American Heart Association

 

#AHA21 – [News release – not published yet] RCT: Long-term, low-dose aspirin did not affect risk of dementia in adults with type 2 diabetes.

16 Nov, 2021 | 08:30h | UTC

Long-term, low-dose aspirin did not affect risk of dementia in adults with type 2 diabetes – American Heart Association

Original Study: Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes

 

#AHA21 – Among patients with intermittent atrial fibrillation, n-of-1 trials with 466 patients found alcohol, but not caffeine, increased the risk of atrial fibrillation events.

16 Nov, 2021 | 08:29h | UTC

Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation: The I-STOP-AFib Randomized Clinical Trial – JAMA Cardiology (free for a limited period)

Commentary: Avoiding AF Triggers Doesn’t Improve Quality of Life: I-STOP-AFib – TCTMD

 

Commentary on Twitter

 

#AHA21 – M-A: Among patients with left main coronary disease, there was no statistically significant difference in 5-year all-cause death between percutaneous coronary intervention with drug-eluting stents vs. coronary artery bypass grafting.

16 Nov, 2021 | 08:31h | UTC

Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis – The Lancet (free registration required)

Commentary: No Mortality Difference Between PCI and CABG for Left Main PCI: Meta-analysis – TCTMD

 

Review: Treatment landscape of triple-negative breast cancer — expanded options, evolving needs.

16 Nov, 2021 | 08:23h | UTC

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs – Nature Reviews Clinical Oncology (free for a limited period)

 

Commentary on Twitter

 

Systematic Review: Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

16 Nov, 2021 | 08:25h | UTC

Summary: Immunosuppressive treatment for adults with idiopathic membranous nephropathy – Cochrane Library

Original Study: Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome – Cochrane Library

 

M-A: Prediction of extubation outcome in critically ill patients.

16 Nov, 2021 | 08:27h | UTC

Prediction of extubation outcome in critically ill patients: a systematic review and meta-analysis – Critical Care

 

Review and algorithm: Dysphagia aortica.

16 Nov, 2021 | 08:19h | UTC

Dysphagia aortica – European Surgery

 

Review: Cardiac device troubleshooting in the intensive care unit.

16 Nov, 2021 | 08:21h | UTC

Cardiac device troubleshooting in the intensive care unit: an educational review – European Heart Journal. Acute Cardiovascular Care

 

Commentary on Twitter

 

Decarbonising healthcare in low and middle income countries: potential pathways to net zero emissions.

16 Nov, 2021 | 08:15h | UTC

Decarbonising healthcare in low and middle income countries: potential pathways to net zero emissions – The BMJ

 

Commentary on Twitter

 

Review | Glycemic management in diabetes: old and new approaches.

16 Nov, 2021 | 08:17h | UTC

Glycaemic management in diabetes: old and new approaches – The Lancet Diabetes & Endocrinology (free registration required)

 

Commentary on Twitter

 

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab.

16 Nov, 2021 | 08:14h | UTC

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases – The University of Texas MD Anderson Cancer Center

Original Study: Study: Combination Immunotherapy for Melanoma Brain Metastases

Related: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

 

Podcast | Obstetrics for the Internist: What to Expect.

16 Nov, 2021 | 08:18h | UTC

#305 OB for the Internist: What to Expect – The Curbsiders

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.